^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    surovatamig (AZD0486)

    i
    Other names: AZD0486, TNB-486, AZD-0486
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    CD3 agonist, CD19 inhibitor
    Related drugs:
    Associations

    News

    Trials
    18d
    T-cell engaging antibodies for B-cell lymphomas. (PubMed, Semin Hematol)
    This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refractory B-cell lymphomas. All 4 CD20 × CD3 BsAbs are approved as third-line and beyond therapies: mosunetuzumab for follicular lymphoma (FL), glofitamab for diffuse large B-cell lymphoma (DLBCL), and epcoritamab and odronextamab for both FL and DLBCL (the latter in European Union only)...Multiple studies are currently evaluating these agents in both the relapsed/refractory and frontline settings, either as monotherapy or in combination with other agents. This review summarizes the efficacy and safety of each agent across B-cell lymphoma subtypes, along with their dosing schedules and CRS mitigation strategies.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab) • surovatamig (AZD0486)
    2ms
    ASSURO: Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    surovatamig (AZD0486)
    2ms
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    3ms
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=276, Recruiting, AstraZeneca | Trial completion date: Apr 2031 --> Feb 2028 | Trial primary completion date: Apr 2031 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    4ms
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    4ms
    ASSURO: Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    surovatamig (AZD0486)
    5ms
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=276, Recruiting, AstraZeneca | N=180 --> 276
    Enrollment change
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    5ms
    SYRUS: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (clinicaltrials.gov)
    P1/2, N=142, Recruiting, AstraZeneca | Trial primary completion date: Jul 2026 --> Nov 2026
    Trial primary completion date
    |
    surovatamig (AZD0486)
    9ms
    SOUNDTRACK-F1: A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (clinicaltrials.gov)
    P3, N=1015, Recruiting, AstraZeneca | Trial completion date: Feb 2035 --> Nov 2031 | Trial primary completion date: Apr 2031 --> Nov 2031
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    9ms
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=317, Recruiting, AstraZeneca | N=231 --> 317 | Trial completion date: Jan 2027 --> Apr 2028 | Trial primary completion date: Jan 2027 --> Apr 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    12ms
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=180, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Jan 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    1year
    AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (clinicaltrials.gov)
    P2, N=240, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    surovatamig (AZD0486)